News

Biogen and Stoke Therapeutics have presented encouraging 3-year open-label extension (OLE) data for zorevunersen, an antisense oligonucleotide (ASO) for...

Terumo Corporation’s acquisition of Organox for $1.5 billion marks a significant leap into the organ transplantation sector, a market...

Lecanemab, co-marketed by Eisai and Biogen as Leqembi®, has launched in Austria and is slated for imminent release in...

Clinuvel Pharmaceuticals, an Australian-listed biopharmaceutical company specializing in treatments for rare and severe skin disorders, is planning to upgrade...

Biosyent Inc. reports robust financial results for Q2 and H1 2025, demonstrating continued growth across its Canadian pharmaceutical, international...

Iovance Biotherapeutics, a leader in the burgeoning field of tumor-infiltrating lymphocyte (TIL) therapies, recently granted stock options to 20...

Eisai and Biogen have launched Leqembi, their anti-amyloid beta monoclonal antibody, in Austria and Germany, marking the drug’s first...

Terumo Corporation’s acquisition of Organox for $1.5 billion marks a significant leap into the burgeoning organ transplantation sector. This...

Biosyent Inc. reports robust financial results for Q2 and H1 2025, demonstrating consistent growth across its Canadian pharmaceutical, international...

Telix Pharmaceuticals reported strong H1 2025 results, with a 63% year-over-year revenue increase to $390.4 million, keeping the company...